Shelia M. Violette - Mar 25, 2024 Form 3 Insider Report for Homology Medicines, Inc. (QTTB)

Role
Chief Scientific Officer
Signature
/s/ Eric Bell, Attorney-in-Fact
Stock symbol
QTTB
Transactions as of
Mar 25, 2024
Transactions value $
$0
Form type
3
Date filed
3/27/2024, 05:32 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding QTTB Common Stock 36.3K Mar 25, 2024 By Violette Holdings LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding QTTB Stock Option (Right to Buy) Mar 25, 2024 Common Stock 4.36K $3.13 Direct F2
holding QTTB Stock Option (Right to Buy) Mar 25, 2024 Common Stock 13.5K $3.13 Direct F2
holding QTTB Stock Option (Right to Buy) Mar 25, 2024 Common Stock 38.9K $7.29 Direct F3
holding QTTB Stock Option (Right to Buy) Mar 25, 2024 Common Stock 13.3K $7.29 Direct F4
holding QTTB Stock Option (Right to Buy) Mar 25, 2024 Common Stock 17.5K $7.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
F2 The shares underlying this option are fully vested and exercisable as of the date hereof.
F3 The shares underlying this option vest and become exercisable in sixteen (16) equal quarterly installments following December 2, 2020, subject to the Reporting Person's continued service on each such vesting date.
F4 25% of the shares underlying this option vested and became exercisable on March 15, 2022, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5 25% of the shares underlying this option vested and became exercisable on December 17, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney